3,4-Dihydroxybenzylamine hydrobromide NEW
| Price | $34 |
| Package | 200mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: 3,4-Dihydroxybenzylamine hydrobromide | CAS No.: 16290-26-9 |
| Purity: 97.28% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | 3,4-Dihydroxybenzylamine hydrobromide |
| Description | 3,4-Dihydroxybenzylamine hydrobromide (NSC-263475 hydrobromide) inhibits DNA polymerase activity in melanoma cells and displays growth inhibitory activity in melanoma cell lines with varying degrees of tyrosinase activity. |
| Cell Research | Cell Line: Human and Murine Melanoma Cell Lines; Non-Melanoma Cell Lines Concentration: 1 μM-10 mM Incubation Time: 48 hours [1] |
| Animal Research | Animal Model: C57BL/6 mice with B6D2F1 cells Dosage: 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg Administration: Intraperitoneal injection [2] |
| In vitro | 3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) inhibits the growth of melanoma cell lines with IC50 values of 30, 84, 90, and 68 μM for SK-MEL-30, SK-MEL-2, SK-MEL-3, and RPMI-7951 cells, respectively, and exhibits IC50 values of 10, 25, 67, and 184 μM for S91A, S91B, L1210, and SCC-25 cells. Cytotoxicity in SK-MEL-2 and SK-MEL-28 is enhanced by buthionine sulfoximine (BSO), decreasing the IC50 values of 3,4-DHBA by 127% in SK-MEL-28 and by 148% in SK-MEL-2 cells[1]. |
| In vivo | 3,4-Dihydroxybenzylamine hydrobromide (200, 400, 600 and 800 mg/kg; i.p.; 21 days) has different effects at different doses, the median life-span are 17, 24.5, 26, 29 and 25 days respectively. 3,4-Dihydroxybenzylamine hydrobromide (1000 mg/kg; i.p.; 7 days) has the least toxic effect in non-tumor-bearing B6D2F1 mice,and mice is tolerated at this dose[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 80 mg/mL (363.54 mM), Sonication is recommended. |
| Keywords | NSC-263475 Hydrobromide | Inhibitor | DNA polymerase | Tumor | NSC263475 | melanoma | NSC-263475 | DNA/RNA Synthesis | 3,4-Dihydroxybenzylamine | inhibit | 3,4Dihydroxybenzylamine hydrobromide | tyrosinase | NSC263475 Hydrobromide | NSC 263475 Hydrobromide | NSC 263475 | 3,4-Dihydroxybenzylamine Hydrobromide | 3,4 Dihydroxybenzylamine hydrobromide |
| Inhibitors Related | Rifampicin | 5-Fluorouracil | Ribavirin | Guanidine hydrochloride | 2,4-D | Resveratrol | Acyclovir | Thymidine | Temozolomide | Folic acid |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1350.00/1KG |
VIP4Y
|
Baoji Guokang Bio-Technology Co., Ltd.
|
2021-06-02 | |
| $10.00/25kg |
VIP2Y
|
Enki Biopharmaceuticals (Shanghai) Limited
|
2023-11-01 | |
| $34.00/200mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY